Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05502315 · ClinicalTrials.gov registry record · Phase 2
Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
A Phase 2 study of Metastatic Cancer and Castration-resistant Prostate Cancer, sponsored by Rana McKay, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
- 4
- Study locations
NCT05502315 is a Phase 2 study of Metastatic Cancer and Castration-resistant Prostate Cancer that is actively recruiting participants, run by Rana McKay, MD. The registered enrollment target is 47 participants, below the 443-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (89% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT05502315, a Phase 2 study of Metastatic Cancer and Castration-resistant Prostate Cancer, is actively recruiting participants, sponsored by Rana McKay, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a multicenter, single-arm, two-stage open-label phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer (CRPC).
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Cabozantinib
Study Locations (4)
California
- University of California San Diego - La Jolla
Illinois
- University of Chicago Medical Center - Chicago
Texas
- University of Texas Southwestern Medical Center - Dallas
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2023-02-02 |
| Est. Completion | 2027-04-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05502315
The ClinicalTrials.gov registry entry for NCT05502315 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 443-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (89% lower). The listed sponsor is Rana McKay, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT05502315 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Illinois, Texas.
Frequently Asked Questions
What is clinical trial NCT05502315 about?
NCT05502315 is a clinical study titled "Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer". This is a multicenter, single-arm, two-stage open-label phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer (CRPC).
What is the current status of trial NCT05502315?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2023-02-02. Estimated completion is 2027-04-12.
What conditions does trial NCT05502315 study?
This clinical trial studies the following conditions: Metastatic Cancer, Castration-resistant Prostate Cancer.
What interventions are being tested in trial NCT05502315?
The interventions under investigation include: Nivolumab (DRUG), Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT05502315?
This trial is sponsored by Rana McKay, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05502315 being conducted?
This trial has 4 study locations across California, Illinois, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
RECRUITING · Phase 2
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Biomarkers to Detect Endocrine Therapy Resistance
RECRUITING · Phase 2
-
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
RECRUITING · Phase 2
-
Definitive Radiation for High-Risk Spine Metastases
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.